LGALS8: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of LGALS8. The page also collects GeneMedi's different modalities and formats products for LGALS8 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the LGALS8 target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Introcelluar Protein.
This gene encodes a member of the galectin family. Galectins are beta-galactoside-binding animal lectins with conserved carbohydrate recognition domains. The galectins have been implicated in many essential functions including development, differentiation, cell-cell adhesion, cell-matrix interaction, growth regulation, apoptosis, and RNA splicing. This gene is widely expressed in tumoral tissues and seems to be involved in integrin-like cell interactions. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008]
Target ID | GM-IP2573 |
Target Name | LGALS8 |
Gene ID | 3964,56048,116641,710375,479193,101101669,506977,100050491 |
Gene Symbol and Synonyms | 1200015E08Rik,D13Ertd524e,Gal-8,galectin-8,Lgals-8,LGALS8,PCTA-1,PCTA1,Po66-CBP |
Uniprot Accession | O00214,Q62665 |
Uniprot Entry Name | LEG8_HUMAN,LEG8_RAT |
Protein Sub-location | Introcelluar Protein |
Category | |
Disease | Prostate Cancer |
Gene Ensembl | ENSG00000116977 |
Target Classification | N/A |
Pre-made anti-LGALS8 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-LGALS8 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-LGALS8 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Antibody Name | Species | Format | Classified by tag | Detail |
Anti-LGALS8 monoclonal antibody | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | mab | Detail |
Recombinant multi-species LEG8/ LGALS8/ Gal-8 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine LGALS8 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Products Name | Species | Expression Platform | Detail |
LGALS8 protein | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | Mammalian cell | Detail |